We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellectricon Launches World’s First System for High Throughput RNAi Screening
Product News

Cellectricon Launches World’s First System for High Throughput RNAi Screening

Cellectricon Launches World’s First System for High Throughput RNAi Screening
Product News

Cellectricon Launches World’s First System for High Throughput RNAi Screening


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellectricon Launches World’s First System for High Throughput RNAi Screening"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellectricon has announced the launch of the new Cellaxess® HT System. According to company, Cellaxess® HT is world’s first fully automated high throughput transfection system that can enable reagent-free delivery of genetic material to a wide range of biologically relevant cell types.

The system will be introduced at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6-10.

Cellectricon has developed Cellaxess® HT in close collaboration with research groups to meet the increasing demand for a technology capable of genome-wide RNAi screening.

"We are very pleased to meet the industry’s demand by bringing this state-of-the-art system to the market.” says Dr. Mattias Karlsson, CEO of Cellectricon. “Cellaxess ® HT will revolutionize target discovery by opening the door to using more biologically relevant cell types in genome-wide RNAi screening.”

Advertisement